$RVMD $DRTS = New Pancreatic Standard of Care
What many miss about daraxonrasib’s remarkable median overall survival benefit is that its objective response rate remains only about one third of patients.
In the Phase 3 RASolute 302 trial, daraxonrasib roughly doubled median overall survival versus chemotherapy (13.2 vs 6.7 months), yet the ORR was 31.6% in the overall population.
That distinction is critical.
Daraxonrasib may become the powerful systemic backbone PDAC has been waiting for, but it does not appear to eliminate the primary tumor in most patients. Instead, it may allow many patients to live significantly longer while still carrying residual pancreatic tumor burden.
In pancreatic cancer, that matters enormously.
The primary tumor is not just a passive bystander; it can drive some of the most devastating clinical complications of the disease, including severe pain, jaundice, bile-duct obstruction, bowel obstruction, malnutrition, cachexia, and loss of quality of life.
This is precisely where Alpha Tau’s Alpha DaRT could become highly complementary.
DaRT is not trying to compete with daraxonrasib as a systemic therapy. It is aiming at a different and potentially crucial battlefield: local tumor control.
By delivering potent alpha radiation directly into the pancreatic tumor through minimally invasive EUS-guided placement, Alpha DaRT offers a targeted way to attack the primary tumor while potentially avoiding the cumulative toxicity burden of adding yet another systemic agent.
Early pancreatic data make this thesis especially compelling.
Alpha DaRT has already shown strong local disease-control signals, including reported 100% local DCR in evaluable patients from pooled pancreatic analyses.
If daraxonrasib controls systemic RAS-driven disease and extends survival, Alpha DaRT may become the local-control partner that helps convert longer survival into better survival — not merely more months alive, but more months with reduced local progression risk, fewer tumor-driven complications, and potentially better quality of life.
Together, this could represent a powerful new multimodal approach in PDAC: systemic RAS inhibition to suppress the biology driving metastatic disease, paired with precise local alpha radiation to control the primary tumor that continues to cause pain, obstruction, and clinical deterioration.
Daraxonrasib may change how long patients live. Alpha DaRT may help change how well they live during that extended survival window.
@FDA, are you with us? Daraxonrasib creates time; Alpha DaRT likely makes that time more clinically meaningful.